Back to Search
Start Over
Biogen boosts MS drug portfolio.
- Source :
-
C&EN Global Enterprise . 12/4/2017, Vol. 95 Issue 48, p12-12. 1p. - Publication Year :
- 2017
-
Abstract
- The article reports on the plan of U.S. biotechnology company Biogen to take over the development of ALKS 8700, an Alkermes small-molecule drug for multiple sclerosis (MS) which is in Phase III clinical trials and will compete with Biogen's MS drug Tecfidera.
- Subjects :
- *MULTIPLE sclerosis treatment
Subjects
Details
- Language :
- English
- ISSN :
- 24747408
- Volume :
- 95
- Issue :
- 48
- Database :
- Academic Search Index
- Journal :
- C&EN Global Enterprise
- Publication Type :
- Periodical
- Accession number :
- 126624106
- Full Text :
- https://doi.org/10.1021/cen-09548-buscon9